Introduction Fexofenadine, the primary metabolite of terfenadine, is a selective and peripherally acting Hl receptor antagonist and has been developed as a non-sedating H1 antihistaminic drug. In clinical studies, it is used for the treatment of seasonal allergic rhinitis and chronic urticaria without producing sedation.